Do analysts rate XLO or LNAI?

Xilio Therapeutics presently has a consensus target price of $28.00, suggesting a potential upside of 263.64%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend LNAI or MREO?

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 937.68%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mereo BioPharma Group 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Is LNAI or MREO more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Mereo BioPharma Group N/A -81.28% -70.45%

Do analysts recommend LNAI or TIL?

Instil Bio has a consensus target price of $66.00, suggesting a potential upside of 717.84%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger earnings & valuation, LNAI or TIL?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is LNAI or TIL more profitable?

Instil Bio's return on equity of -39.76% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Instil Bio N/A -39.76% -22.38%

Do analysts recommend LNAI or GOSS?

Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is LNAI or GOSS more profitable?

Lunai Bioworks has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Gossamer Bio -324.82% N/A -96.10%

Do analysts rate ATYR or LNAI?

aTyr Pharma presently has a consensus price target of $21.00, suggesting a potential upside of 4,368.09%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe aTyr Pharma is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATYR or LNAI more profitable?

aTyr Pharma's return on equity of -100.14% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Lunai Bioworks N/A -1,243.45% -1,617.76%

Lunai Bioworks (LNAI) Competitors

$2.45 -0.47 (-16.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 +0.12 (+4.90%)

As of 07:51 PM Eastern

Compare

LNAI vs. XLO, MREO, TIL, GOSS, and ATYR

Should you buy Lunai Bioworks stock or one of its competitors? MarketBeat compares Lunai Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lunai Bioworks include Xilio Therapeutics (XLO), Mereo BioPharma Group (MREO), Instil Bio (TIL), Gossamer Bio (GOSS), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry.

How does Lunai Bioworks compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Xilio Therapeutics had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 1 mentions for Xilio Therapeutics and 0 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 0.62 beat Xilio Therapeutics' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
Lunai Bioworks	Positive

Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Xilio Therapeutics presently has a consensus target price of $28.00, suggesting a potential upside of 263.64%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lunai Bioworks has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Xilio Therapeutics has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.16	-$35.04M	-$3.55	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Summary

Xilio Therapeutics beats Lunai Bioworks on 10 of the 15 factors compared between the two stocks.

How does Lunai Bioworks compare to Mereo BioPharma Group?

Lunai Bioworks (NASDAQ:LNAI) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lunai Bioworks has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

In the previous week, Lunai Bioworks' average media sentiment score of 0.62 beat Mereo BioPharma Group's score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Mereo BioPharma Group	Neutral

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 937.68%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Mereo BioPharma Group has higher revenue and earnings than Lunai Bioworks. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Mereo BioPharma Group	$500K	99.99	-$41.88M	-$0.05	N/A

Mereo BioPharma Group's return on equity of -81.28% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Summary

Mereo BioPharma Group beats Lunai Bioworks on 9 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Instil Bio?

Lunai Bioworks (NASDAQ:LNAI) and Instil Bio (NASDAQ:TIL) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

In the previous week, Lunai Bioworks' average media sentiment score of 0.62 beat Instil Bio's score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Instil Bio	Neutral

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Instil Bio's return on equity of -39.76% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Instil Bio	N/A	-39.76%	-22.38%

Instil Bio has a consensus target price of $66.00, suggesting a potential upside of 717.84%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Lunai Bioworks has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Summary

Instil Bio beats Lunai Bioworks on 8 of the 11 factors compared between the two stocks.

How does Lunai Bioworks compare to Gossamer Bio?

Lunai Bioworks (NASDAQ:LNAI) and Gossamer Bio (NASDAQ:GOSS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Gossamer Bio has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A

Lunai Bioworks has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Gossamer Bio	-324.82%	N/A	-96.10%

Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,757.14%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Lunai Bioworks has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 7.2% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Gossamer Bio had 15 more articles in the media than Lunai Bioworks. MarketBeat recorded 15 mentions for Gossamer Bio and 0 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 0.62 beat Gossamer Bio's score of 0.21 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Gossamer Bio	Neutral

Summary

Gossamer Bio beats Lunai Bioworks on 12 of the 15 factors compared between the two stocks.

How does Lunai Bioworks compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

aTyr Pharma has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

aTyr Pharma has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	242.54	-$74.12M	-$0.73	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

In the previous week, aTyr Pharma's average media sentiment score of 1.90 beat Lunai Bioworks' score of 0.62 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Very Positive
Lunai Bioworks	Positive

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

aTyr Pharma's return on equity of -100.14% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

aTyr Pharma presently has a consensus price target of $21.00, suggesting a potential upside of 4,368.09%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe aTyr Pharma is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

aTyr Pharma beats Lunai Bioworks on 12 of the 14 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$13.24M	$994.16M	$4.25B	$12.46B
Dividend Yield	N/A	4.84%	8.16%	5.34%
P/E Ratio	-6.13	1.49	21.69	23.64
Price / Sales	N/A	127.97	172.86	112.53
Price / Cash	N/A	20.06	52.87	57.17
Price / Book	-0.25	7.92	27.92	6.37
Net Income	-$178.01M	-$4.04M	$109.80M	$337.36M
7 Day Performance	-20.45%	-2.79%	-3.42%	-3.07%
1 Month Performance	-1.84%	66.23%	1.21%	0.37%
1 Year Performance	N/A	110.65%	12.95%	27.87%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.2919 of 5 stars	$2.45 -16.1%	N/A	N/A	$13.24M	N/A	N/A	20	Gap Down
XLO Xilio Therapeutics	1.653 of 5 stars	$8.46 -0.7%	$28.00 +231.0%	-10.9%	$55.63M	$53.48M	N/A	70	Gap Down
MREO Mereo BioPharma Group	3.2388 of 5 stars	$0.34 -0.3%	$3.25 +844.8%	-87.5%	$54.91M	$500K	N/A	40
TIL Instil Bio	2.1613 of 5 stars	$8.07 -0.4%	$66.00 +717.8%	-76.3%	$54.73M	N/A	N/A	410
GOSS Gossamer Bio	2.0348 of 5 stars	$0.23 +9.4%	$5.00 +2,065.4%	-85.9%	$54.19M	$48.47M	N/A	180	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. XLO, MREO, TIL, GOSS, and ATYR

How does Lunai Bioworks compare to Xilio Therapeutics?

Summary

How does Lunai Bioworks compare to Mereo BioPharma Group?

Summary

How does Lunai Bioworks compare to Instil Bio?

Summary

How does Lunai Bioworks compare to Gossamer Bio?

Summary

How does Lunai Bioworks compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. XLO, MREO, TIL, GOSS, and ATYR

How does Lunai Bioworks compare to Xilio Therapeutics?

Do institutionals and insiders hold more shares of XLO or LNAI?

Does the media refer more to XLO or LNAI?

Which has more risk & volatility, XLO or LNAI?

Do analysts rate XLO or LNAI?

Is XLO or LNAI more profitable?

Which has stronger valuation & earnings, XLO or LNAI?

Summary

How does Lunai Bioworks compare to Mereo BioPharma Group?

Do institutionals & insiders have more ownership in LNAI or MREO?

Which has more risk and volatility, LNAI or MREO?

Does the media prefer LNAI or MREO?

Do analysts recommend LNAI or MREO?

Which has stronger valuation & earnings, LNAI or MREO?

Is LNAI or MREO more profitable?

Summary

How does Lunai Bioworks compare to Instil Bio?

Does the media prefer LNAI or TIL?

Do institutionals & insiders hold more shares of LNAI or TIL?

Is LNAI or TIL more profitable?

Do analysts recommend LNAI or TIL?

Which has more volatility and risk, LNAI or TIL?

Which has stronger earnings & valuation, LNAI or TIL?

Summary

How does Lunai Bioworks compare to Gossamer Bio?

Which has better earnings & valuation, LNAI or GOSS?

Is LNAI or GOSS more profitable?

Do analysts recommend LNAI or GOSS?

Which has more volatility and risk, LNAI or GOSS?

Do insiders & institutionals believe in LNAI or GOSS?

Does the media prefer LNAI or GOSS?

Summary

How does Lunai Bioworks compare to aTyr Pharma?

Which has more volatility and risk, ATYR or LNAI?

Which has higher earnings and valuation, ATYR or LNAI?

Does the media refer more to ATYR or LNAI?

Do insiders and institutionals have more ownership in ATYR or LNAI?

Is ATYR or LNAI more profitable?

Do analysts rate ATYR or LNAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools